Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.39 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.39 |
| ▸ | CCR8 | P51685 | 1/20 | 0.35 |
| ▸ | S100A9 | P06702 | 1/20 | 0.32 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11055567 | 0.81 | ALDH1A1 (0.45) | KMT2AALDH1A1CHRNB4CHRNA3 | |
| SCHEMBL31748652 | 0.81 | AURKA (0.41) | KMT2AALDH1A1CHRNB4CHRNA3IDO1 | |
| SCHEMBL8165345 | 0.78 | ESR1 (0.39) | KMT2AALDH1A1 | |
| SCHEMBL18031353 | 0.78 | ALDH1A1 (0.38) | KMT2AALDH1A1 | |
| SCHEMBL31747917 | 0.78 | MAPT (0.44) | KMT2AALDH1A1 | |
| SCHEMBL31748352 | 0.76 | ALDH1A1 (0.37) | KMT2AALDH1A1CHRNB4CHRNA3 | |
| SCHEMBL6192864 | 0.76 | HDAC4 (0.38) | KMT2AALDH1A1CHRNB4CHRNA3IDO1 | |
| SCHEMBL31747886 | 0.75 | AKT1 (0.42) | KMT2AALDH1A1 | |
| SCHEMBL31747957 | 0.75 | NOTUM (0.46) | KMT2AALDH1A1CHRNB4CHRNA3 | |
| SCHEMBL31747993 | 0.73 | ALDH1A1 (0.50) | KMT2AALDH1A1IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7579353-B2 | Pyridinone derivatives against malaria | GLAXO GROUP LIMITED (GB) | 2009-08-25 | — | — | US | disclosed |
| US-20080287461-A1 | Pyridinone Derivatives Against Malaria | GLAXO GROUP LIMITED (GB) | 2008-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287461-A1 | Pyridinone Derivatives Against Malaria | G6PD, PNPO, PLPBP | KMT2A 3141/4885ALDH1A1 287/4885CHRNB4 3409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.